Abstract:
The present invention is directed to a method of isolating a target species (e.g., target nucleic acid species) from a mixture. In the methods of the present invention, the mixture is combined with solid phase carriers having a surface comprising multiple functional groups one of which reversibly and selectively binds the target species. In a particular embodiment, the mixture is combined with solid phase carriers having a first functional group which reversibly binds nucleic acids and a second functional group which selectively and reversibly binds the target nucleic acid species, thereby producing a first combination. The first combination is maintained under conditions appropriate for binding of the nucleic acids to the first functional group and binding of the target nucleic acid species to the second functional group. The solid phase carriers are separated from the first combination, and combined with an agent (e.g., buffer) that selectively removes (e.g., elutes) either the nucleic acid from the first functional group or the target nucleic acid species from the second functional group of the solid phase carriers, thereby isolating a target nucleic acid species from a mixture comprising a plurality of nucleic acid species.
Abstract:
Methods and systems are presented for recommending similar questions to one that a user has entered into a search engine. Previously-entered questions are subject to a clustering algorithm and placed into a hierarchy of clusters, with clusters set within clusters. For each cluster within the hierarchy, a representative vector, based on feature vectors of the items within the cluster, is calculated. A feature vector for the user's question is calculated and used, along with the representative vectors at each level in the hierarchy, to traverse and navigate the cluster hierarchy. When a leaf cluster is found, the items in the leaf cluster, such as the previously-entered questions are returned to the user. A subset of items in the leaf cluster, or items from other leaf clusters within a branch cluster, can be selected based on the number of items desired to be returned.
Abstract:
The present invention is directed to a method of isolating a target species (e.g., target nucleic acid species) from a mixture. In the methods of the present invention, the mixture is combined with solid phase carriers having a surface comprising multiple functional groups one of which reversibly and selectively binds the target species. In a particular embodiment, the mixture is combined with solid phase carriers having a first functional group which reversibly binds nucleic acids and a second functional group which selectively and reversibly binds the target nucleic acid species, thereby producing a first combination. The first combination is maintained under conditions appropriate for binding of the nucleic acids to the first functional group and binding of the target nucleic acid species to the second functional group. The solid phase carriers are separated from the first combination, and combined with an agent (e.g., buffer) that selectively removes (e.g., elutes) either the nucleic acid from the first functional group or the target nucleic acid species from the second functional group of the solid phase carriers, thereby isolating a target nucleic acid species from a mixture comprising a plurality of nucleic acid species.
Abstract:
A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
Abstract:
A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
Abstract:
Described herein are systems and methods for cryogenic fluid delivery. The systems may include a pressure vessel containing a cryogenic fluid formed of liquid and vapor that is connected to a use device via a withdrawal line. The withdrawal line connects to the cryogenic fluid in the pressure vessel via two routes, a liquid tube and a vapor line. The vapor line may include a back-pressure regulator that opens the vapor line depending on pressure in the system. The withdrawal line may include a pressure relief valve that exerts pressure on the liquid tube. A bypass line may connect the withdrawal line to the liquid tube. The bypass line has a check valve that permits free flow of cryogen from the withdrawal line to the liquid tube via the bypass line while prohibiting cryogen flow from the pressure vessel through the bypass line. The methods employ the systems described herein.
Abstract:
Described herein are at least systems and methods for cryogenic fluid delivery which utilize pumpless delivery of cryogenic fluid. The systems and methods utilize hydraulic pressure, saturation pressure, or a combination of both hydraulic pressure and saturation pressure to deliver cryogen to a use device, such as an engine.
Abstract:
Described herein are systems and methods for cryogenic fluid delivery. The systems may include a pressure vessel containing a cryogenic fluid formed of liquid and vapor that is connected to a use device via a withdrawal line. The withdrawal line connects to the cryogenic fluid in the pressure vessel via two routes, a liquid tube and a vapor line. The vapor line may include a back-pressure regulator that opens the vapor line depending on pressure in the system. The withdrawal line may include a pressure relief valve that exerts pressure on the liquid tube. A bypass line may connect the withdrawal line to the liquid tube. The bypass line has a check valve that permits free flow of cryogen from the withdrawal line to the liquid tube via the bypass line while prohibiting cryogen flow from the pressure vessel through the bypass line. The methods employ the systems described herein.
Abstract:
A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
Abstract:
A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.